Nathalie Van den Berghe

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

Bram Verstockt, Erwin Dreesen, Maja Noman et al. · Journal of Crohn s and Colitis · 2019 · 121 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients

Nathalie Van den Berghe, Bram Verstockt, Sophie Tops et al. · Journal of Gastroenterology and Hepatology · 2018 · 33 citations

Life Sciences, Immunology, Pharmacology +17

Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis

Nathalie Van den Berghe, Eline De Keyser, Rani Soenen et al. · British Journal of Dermatology · 2019 · 27 citations · Full text

Medicine, Dermatology, Pharmacology +13

Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis

Jessica Vandenhaute, Anneleen Avau, Jessica Filtjens et al. · The Journal of Immunology · 2019 · 25 citations

Life Sciences, Immunology, Pathology +17

Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations

Sumin Bian, Nathalie Van den Berghe, L Vandersmissen et al. · Journal of Pharmaceutical and Biomedical Analysis · 2020 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15